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Abstract 
A synthesis of cyclobutane nucleosides is described.  The method involved the triflation of a β-
hydroxymethyl-cyclobutanone and its subsequent displacement by a 6-chloropurinyl anion to 
generate N-7 and N-9 regioisomers.  The stereoselective reduction of the N-alkylated ketones 
yielded the cis-alcohols quantitatively and the geometric configuration was confirmed by 
spectroscopic data and X-ray diffraction.  Photolysis of N-7 and N-9 coupled ketones was carried 
out in methanol using quartz tubes to promote ring-expansion isonucleoside products.  Photolysis 
did not yield any ring-expansion or cycloelimination products, rather, the products are suspected 
to be cyclopropanes from decarbonylation of the ketones, since these are less polar and show 
shielding of protons in their corresponding NMR spectra, consistent with substituted 
cyclopropanes.  
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Chapter 1 
1.0 Introduction 
1.1 Biochemistry of Natural Nucleosides 
“Nucleoside” is a term that was first introduced in 1909 by Levene and Jacob for subunits 
of nucleic acids which were isolated by the hydrolysis of nucleic acids.1  Naturally occurring 
nucleosides consist of a purine (adenine and guanine) or pyrimidine base (uracil, cytosine and 
thymine), bonded to a furanose sugar moiety such as β-D-ribofuranose or β-D-
deoxyribofuranose. 
 
Figure 1- Naturally occurring purine and pyrimidine nucleobases 
Natural nucleosides (Figure 1) play an essential role in regulatory and biosynthetic 
processes.  Since nucleosides are the building blocks of nucleic acids, the information stored in 
deoxyribonucleic acid (DNA) depends solely on the sequence of nucleosides.  Consequently, 
they are associated with conservation, replication and transcription of genetic information. 
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Figure 2- Hydrogen bond interactions between complimentary nitrogenous bases in DNA that 
stabilize the DNA double helix 
DNA and RNA consist of strands that are held together by hydrogen bonds through 
complimentary base pairing of nucleosides (Figure 2).   The mechanism of replication and 
transcription of DNA into RNA and DNA also occurs with the polymerization of nucleosides.  
The expression of proteins also proceeds via a biosynthetic process in which DNA is transcribed 
into messenger RNAs (mRNAs).  mRNAs are then translated into protein amino-acid sequences 
with the involvement of transfer RNAs (tRNAs) that carry amino-acids and pair up with their 
complementary codon sequence (a set of three base-pair sequences) and act as adapters, between 
the mRNA and amino acids. 
 
1.2 Conception and classification of Nucleoside analogues  
Upon intracellular phosphorylation by kinases, nucleosides can assume a biologically 
active role.  Thus, the conception of analogues of phosphorylated nucleosides, commonly 
referred to as nucleotides, show significant chemotherapeutic potential in their ability to interfere 
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with biological processes involved in the rapid proliferation of tumour cells.  However, 
nucleotides exist as dianonic species that are unable to pass easily through cellular membranes.  
Nucleosides and their analogues are neutral molecules that can enter the cell, which can then 
assume the therapeutic role upon intracellular phosphorylation by kinases via three main 
pathways: enzyme inhibition, incorporation into DNA & RNA, and DNA synthesis inhibition 
(Figure 3). 
 
 
Figure 3- Mechanism of action of nucleoside analogues.2 
Since natural nucleosides consist of two parts, a sugar moiety and a nucleobase, these two 
parts are susceptible to structural modifications for the design of nucleoside analogues.  Several 
structural modifications can be made to the sugar moiety such as: the inversion of configuration 
from D to L, anomeric inversion of β to α, elimination or substitution of hydroxyl groups, 
modification to the ring size (ex. oxetanes, pyranose etc.), substitution of one or more atoms in 
the ring with heteroatoms, addition of various functional groups, changes to the nucleosidic 
linkage to the sugar (by a C-C or C-heteroatom linkage), and lastly changes to the heterocyclic 
base (nucleobase-modified nucleosides).  Alteration of the nucleobase-furanose connectivity on 
C-2 to another position gives isonucleosides, and the absence of a methylene group on C-5 yields 
a nornucleoside (Figure 4). 
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Figure 4- Possible modifications for potential nucleoside analogues 
1.3 Nucleobase-modified nucleoside analogues  
Nucleoside analogues of thiopurines and fluorinated pyrimidines as modified nucleobases 
have demonstrated significant antiviral and anticancer activities.  Elion’s group discovered that 
substitution of guanine and hypoxanthine with sulfur at the 6 position resulted in inhibition of 
purine synthesis.  6-Mercaptopurine (6-MP) and 6-thioguanine (6-TG) nucleobases were shown 
to metabolize to the cytotoxic nucleoside 5’monophosphates that inhibit 
phosphoribosylpyrophosphate amidotransferase preventing the de novo purine biosynthesis.  
They also prevented the conversion of the inosine 5’monophosphate, the phosphorylated 
hypoxanthine nucleoside, to the guanine and adenine nucleotides.1  They were shown to exhibit 
potent anticancer activities against various rodent tumours. 6-MP was FDA approved in 1953 for 
treatment of pediatric acute lymphocytic leukemia, a cancer of blood and bone marrow that leads 
to overproduction of immature lymphocytes.  It still remains as a standard treatment for acute 
lymphocytic leukemia as well as autoimmune disorders such as psoriasis, ulcerative colitis and 
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rheumatoid arthritis.  6-TG is administered for treatment of acute myelogenous leukemia, a 
cancer of white blood cells that interferes with the production of normal white blood cells.   
 
Fluorinated drugs provide added stability without significantly altering the geometry of 
the non-fluorinated molecule, since hydrogen and fluorine are comparable in size and bond 
length, with a van der Waals radii of 1.20A˚vs1.47A˚ and average bond lengths of 1.08-1.10 1Å 
(C-H) vs. 1.26-1.411Å (C-F).  The strength of C-F bonds (116 kcal/mol) also ensures greater 
metabolic stability compared to the C-H bonds (99 kcal/mol)3 which leads to a greater 
bioavailability.  Nucleosides of 5-fluorinated pyrimidines along with the nucleobases themselves 
are an essential class of antitumour agents that were first discovered by  Rutman and co-workers 
in 1954.  They observed the increased uptake of uracil and conversion of deoxyuridine-5’-
monoophosphate 3, in rat liver tumour cells to thymidine-5’-monophosphate by thymidylate 
synthase.  They speculated that 5-fluorouracil would prevent methylation at the 5-position, thus 
inhibiting thymidylate synthase and decreasing thymidine in cells, and that it would selectively 
target tumor cells since tumour cells displayed a higher uptake of uracil.2  As they speculated, 5-
fluorodeoxyuridine 3 (5-fluorouracil nucleoside) and 5-fluorouracil were found to be potent 
inhibitors of thymidylate synthetase and are currently used for the treatment of breast cancer, and 
solid tumours such as gastrinointestinal tumours.1  The dosage treatment for 6-15 days for 0.5-1 
mg/kg of 3, is comparable to that of 15 mg/kg of 5-fluorouracil weekly.1  Trifluorothymidine 4 
has also been shown to exhibit promising anticancer activity, but it rapidly degrades within the 
body by the enzyme thymidine phosphorylase.  Thus, it is coadministered with tipiracil 
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hydrochloride 5, a thymidine phosphorylase inhibitor with a molar ratio of 2:1 by Taiho 
Pharmaceuticals as TAS-102, with an IC50 of 35 nM. TAS-102 was FDA-approved for patients 
with colorectal cancer in Sept 2015.2 
 
  
 
1.4 Carbocyclic Nucleosides 
Carbocyclic nucleoside analogues contain a methylene in place of oxygen in the sugar 
moiety which increases metabolic stability towards hydrolases and phosphorylases of the C-N 
bond, which is otherwise labile and quite susceptible to cleavage.1,2,4,5  Carbocyclic nucleoside 
analogues are generally non-natural in origin, however some natural-occuring ones include 
Aristeromycin 6 and Neplanocin A 7.  D-(-)-aristeromycin was isolated in 1968 from 
Streptomyces citricolor, whereas neplanocin A was discovered in 1981, both of which have been 
known to exhibit significant anti-tumour and anti-viral activity, and are speculated to inhibit the 
S-adenosyl-L-homocysteine (SAH) hydrolase.5  Norcarbocyclic nucleosides are another class of 
carbocyclic nucleoside analogs that lack a methylene group at C-5’. These were first synthesized 
by Schneller and Trost in 1987.4  These are more specifically referred to as 5’-norcarbocyclic 
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nucleosides and were first synthesized in an attempt at making analogues of neplanocin A and 
aristeromycin that exhibit a lower toxicity.4  It was theorized that the absence of the methylene 
group would prevent phosphorylation and lower activity.  Several research groups have shown 
that the cytotoxicity of these is much lower than Aristeromycin and Neplanocin A and their 
mode of action has been demonstrated to be the inhibition of S_Adenosylhomocysteine 
hydrolase (SAH hydrolase).4 
 
1.5 Synthesis of Nucleoside Analogues 
Various methods exist for the preparation of nucleoside analogues.  One of the main 
routes is the introduction of nucleobases directly onto the sugar moiety. Heterocycles can be 
introduced by direct nucleophilic substitution via an SN2 protocol.  Examples of such are 
addition of a nucleobase to a haloalkane (Scheme 1).6 
 
 
Derivative 9 showed antifungal activity against Candida albicans (ATCC 10145), a fungi 
that grows as yeast and filamentous cells and is a cause of oral and vaginal infections.  
Others have used activated alcohols in the form of tosylates7–11 and triflates.7,12,13  
Tosylates have been employed as intermediates to synthesize biologically active cyclobutane 
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nucleoside analogues against a broad spectrum of herpes viruses (Scheme 2).11
 
The Mitsunobu reaction has also been employed to synthesize various acylic,14–16 
carbocylic15,17–20 and other nucleoside analogues16 under mild conditions in moderate yields.  
Hubert and coworkers have employed the Mitsunobu reaction to prepare a cyclobutene carbovir 
analog (Scheme 3).17  Advantages of the Mitsunobu reaction include mild conditions, one-pot 
reaction, applicability for a variety of purine and pyrimidine bases, and stereospecificity. The 
reaction proceeds with inversion of stereochemistry.  Disadvantages include the production of 
stoichiometric amounts of triphenyl phosphene oxide and a mixture of O- and N-alkylations with 
pyrimidine bases.20 
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Other methods of alkylation with a nucleobase include Michael additions and Trost 
reactions.  These methods are restricted to activated alkene moieties. Trost proposed a highly regio-
and stereoselective synthesis of nucleoside analogues from epoxycycloalkenes 19 with  
 nucleobases (Scheme 4).4 
 
 
1.6 Charge distribution of purines 
The N-alkylation of purines often gives a mixture of N-7- and N-9-alkylated 
regioisomers.  On deprotonation at N-9, the negative charge can be delocalized over three 
centres, N-7, C-8 and N-9.  The negative charge mainly resides at N-9 with a smaller charge 
distribution at the N-7.  Theoretical calculations show a charge distribution of (-0.59) for N-9 and 
(-0.37) on N-7 for 6-chloropurinyl anion and (-0.56) at N-9 centre and (-0.45) for N-7 for the 
parent purine anion.21 
 
1.7 Cyclobutanones as precursors to nucleoside analogues 
Cyclobutanones can be readily synthesized by a [2+2] thermal cyloaddition of an alkene 
with dichloroketene, prepared in situ by dechlorination of trichloroacetyl chloride, followed by 
dechlorination of the resulting dichlorocyclobutanone (Scheme 5).21–25  N-Alkylation of a 
 10 
nucleobase to the cyclobutanone, followed by either reduction or photochemistry can be used to 
make acylic as well as, four and five-membered ring nucleoside analogues (Eq.1 & 2).21 
 
 
 
1.7.1 Photochemistry of Cyclobutanone 
Cyclobutanones can undergo three different photochemical pathways including: 
cycloelimination, ring-expansion and decarbonylation (Scheme 6).26,27  On exposure to light, 
ketone 35 undergoes excitation to a singlet excited species (S1) 36, by n àπ*transition at a 
wavelength of 300 nm.28,29  In its excited state, it can proceed by α-cleavage to a 1,4-acyl-alkyl 
biradical. The cleavage generally occurs at the more substituted position as a result of radical 
stabilization.  This biradical 37 can lead to a ring-expansion isomerization to an oxa-carbene, 
with retention of stereochemistry 26 of the ring substituents, or cycloelimination to an alkene also 
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with stereochemical retention.  The oxa-carbene can insert into acidic X-H groups such as 
alcohols or water to produce acetals, or acidic N-H to produce amino-acetals.  In the absence of 
acidic carbene scavengers, cycloelimination occurs.  The distribution of cycloelimination and 
ring-expansion products is also dependent on the polarity of the medium. 26  Dimerization is also 
possible in concentrated solutions.26  One proposed mechanism for cycloelimination is the 
formation of the 1, 4 acyl-alkyl biradical followed by a β-cleavage.   This yields a ketene and an 
alkene.  Decarbonylation can occur through the triplet state (T1).  However, this state is rarely 
involved in direct irradiation since the release of strain in ring-expansion and cycloelimination 
from the singlet state makes this pathway very efficient. Decarbonylations of cyclobutanones 
from the triplet state is only accessible by triplet photosensitization in solvents such as acetone or 
in the gaseous phase.30,31 
 
1.8 Proposal 
The objective of this research project was to make four-membered carbocyclic and 
furanose-analogs using cyclobutanones since the biological activities of three, four, five and six 
membered nucleoside analogues have been a target of interest due to the potential antiviral and 
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anticancer activities.  This has led to the synthesis of cyclopropyl,32,33 cyclobutyl11,34,35 and 
cyclopentyl36,37 nucleoside analogs.  Oxetanocin-A (OXT-A) 46 is a naturally occurring four-
membered adenine nucleoside that exhibits antiviral activity and is used as an antibiotic.35 It’s 
activity has motivated others to make carbocyclic analogues such as Cyclobut-A 47 and 
Cyclobut-G 48 which possess selective anti-HIV activity.1,35,38 
 
Due to the interesting photochemical transformation that cyclobutanones can undergo, 
they can potentially be used as precursors to analogues with varying ring sizes for the sugar 
moiety. The reduction of cyclobutanones could give four membered nucleoside analogues that 
could be used as oxetanocin carbocylic analogues. Cylcobutanones can also be used for synthesis 
to create three and five-membered ring nucleoside analogues.   
Debenzoylation of 49 can be used to create a cyclobutanone with a hydroxyl methyl at 
the β- position, which can be coupled to purine and pyimidine nucleobases for the preparation of 
homonucleoside analogs of OXT-A (scheme 7).    
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The objective of this research project was to synthesize 52 and 54, a four-membered 
carbocylic and a five-membered ring isonucleoside analog, from reduction or photolysis of 51, 
respectively (Scheme 8). 
 
The photochemical ring expansion of cyclobutanones yields oxacarbenes that can 
insert into alcohols or acidic N-H bonds.39–44  Photochemical ring expansion of 51 followed by 
insertion in H2O or MeOH should give 54, a furanose nucleoside analog. 
 
 
 
 
 
 
 
 
 
 
 
 14 
Chapter 2 
2.0 Results and Discussion 
2.1 Synthesis of substrate 49 
The isolation of OXT-A in 1986, from fermentation of Baccilus megaterium broth with 
an oxetanosyl sugar, demonstrated potent inhibition of HSV-1, HSV-2, HCMV, and HIV-1, 
which motivated chemists to synthesize related analogues.45  Carbocylic analogues, Cyclobut-A 
and Cyclobut-G were synthesized to improve metabolic stability. 
Similarly, our focus was to add to the library of such oxetanoncin analogues from 
cyclobutanone precursors.  A cyclobutanone with a protected hydroxymethyl group on the β-
position, 49 was chosen as the precursor since it is readily synthesized and could be used for a 
variety of novel nucleoside analogues.  Ketone 49 can be prepared from a [2+2] cylcoaddition of 
allyl benzoate 5546 with dichloroketene, generated in situ from dechlorination of TCAC with  
Zn-Cu couple followed by reduction with Zn powder (Eq.3).47 
 
2.2 Debenzoylation of ketoester 49 
 
Debenzoylation of 49 using a saturated solution of NaOMe in methanol48,49 yielded the 
deprotected alcohol 50 in minute quantities with the remaining being indiscriminate 
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decomposition products as evident from the streaking baseline on TLC (EtOAc).  We decided to 
use K2CO3, a milder base, at room temperature which afforded 50 in 75 % yields (Eq.4).  We 
proposed the possibility of decomposition of 50 in basic conditions.  This was supported by the 
observed decrease in yield to 47% when the reaction time was extended to 3 h. 
  The structure of 50 was confirmed by the disappearance of the benzoyl proton signals 
in the aromatic region of the1HNMR spectrum as well as a shift in the bridging methylene peaks 
from 4.50 ppm in the ester to 3.75 ppm for the alcohol.  The shift of the carbonyl peak, of 12 
cm1, from 1787 to 1775 cm1 in the IR spectrum is also evidence of this transformation. 
 
 
Figure 5 – 1H NMR spectrum of alcohol 50 
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2.3 Triflation of alcohol 50 
 
The addition of Hunig’s base followed by a dropwise addition of 
trifluoromethanesulfonic anhydride (Tf2O) to a solution of 50 in CH2Cl2, afforded the triflate 57 
in quantitative yields (Eq.5).  The triflate was not isolated or characterized due to its unstable 
nature.  The structure assignment was confirmed by the observation of deshielding of the 
methylene protons at 𝛿 3.75 ppm (d, J = 6.2 Hz, 2H) for the alcohol 50 to 𝛿	4.68 ppm (d, J = 6.1, 
2H) after triflation in the 1H NMR spectrum of 57. The triflate was highly reactive and not 
sufficiently stable to run 2-D NMR experiments.  Decomposition occurred minutes after 
preparation. 
Triflation did not occur when trifluorosulfonyl chloride was used as the triflating agent, 
and when other conventional bases such as pyridine and trimethylamine were used. 
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Figure 6 – 1H NMR spectrum of crude triflate 57 
 
2.4 N-Alkylation of triflate 57 
The introduction of nucleobases via SN2 attack of the heterocyclic salts on alkyl 
sulfonates, is well documented.6–13  The pKa of purines and pyrimidines is generally between 8 
to 10 and their salts can be readily prepared via deprotonation by inorganic bases such as 
carbonates, hydroxides, hydrides etc. 6–13,49 Thus, we proposed the use of a 6-chloropurinyl salt, 
previously prepared in our lab with similar cyclobutanone derivatives.  The 6-chloropurinyl salt 
was prepared by stirring with potassium hydroxide in acetonitrile with 5% molar tris[2-(2-
methoxyethoxy)ethyl]amine (TDA-1). Subsequent addition of the crude solution of triflate 57, 
afforded a total of 88% N-alkylated products as the N-9 60 and N-7 61 ketones in 51% and 37% 
yields, respectively (Eq.6).  Previous attempts at N-alkylation involved mesylation and tosylation 
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of 50 followed by addition to a solution of the 6-chloropurinyl salt.  The yields were very low (< 
4%) even under elevated temperatures of 60 oC and prolonged reaction time of 24 h.  
 
The observation of N-7 and N-9 alkylations is known with purines due to the negative 
charge distribution for the purinyl and 6-purinyl anions as described previously.  The larger 
negative charge (-0.59) for the 6-chloropurinyl anion 59 resides at N-9 and the smaller charge (-
0.37) resides at N-7 (Scheme 9).21   
 
The TLC of the crude solution showed two major UV-active spots with Rf values of 
0.45 and 0.22 (5% MeOH in CHCl3).  In previous studies, N-alkylation of purine bases to similar 
cyclobutanones often yielded the N-7 alkylated products as the more polar component. The 
methylene protons adjacent to N-7 are more deshielded relative to the corresponding protons of 
the N-9 alkylated products in the 1H NMR spectra.  The methylene protons for the alcohol 50 (𝛿 
3.75, d, J = 6.2 Hz, 2H) and triflate (𝛿 4.68, d, J = 6.1, 2H) were replaced by a set of two new 
methylene peaks at 𝛿 4.54 (d, J = 7.6 Hz, 2H) and 𝛿 4.73 (d, J = 7.6, 2H), with similar coupling 
constants.  The relative ratio was determined to be 1:0.68 by integration.  Also two pairs of 
aromatic peaks at δ 8.78 (s, 1H), 8.17 (s, 1H) and δ 8.92 (s, 1H), 8.32 (s, 1H) with similar 
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relative integral areas of 1:0.6-0.7 were observed.  This is close to the calculated ratio of charge 
localization on N-9 and N-7 (-0.59:-0.37 ≈ 1:0.63).  Furthermore, the IR spectrum showed two 
carbonyl peaks, at 1779 cm-1 and 1777 cm-1 typical of cyclobutanones.  Thus, it was proposed 
that the major product was the N-9 coupled ketone 60 and the minor product was the N-7 
coupled ketone 61.  The major product was separated and confirmed to be 60 based on 1D (1H 
NMR and 13C NMR) and 2D NMR (HSQC and HMBC) experiments. 
  
 
Figure 7 – 1H NMR spectrum of N-9 ketone 60 
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Figure 8 – 13C-NMR spectrum of N-9 coupled ketone 60 
 The N-9 substituted derivatives can be distinguished from N-7 isomers using 2D NMR 
spectroscopy such as HSQC and HMBC.  The regioisomers can be distinguished by first 
identifying the aromatic protons and the carbons on the purine ring, followed by confirmation of 
the relationship between the bridging methylene protons, H-5’, and the purinyl carbon and 
nitrogen atoms.  
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Figure 9 – 1H-13C HSQC of N-9 coupled ketone 60 
The use of HSQC spectroscopy allowed for facile distinction between secondary, tertiary 
and quaternary carbons.  This coupled with HMBC spectroscopy allowed for the identification of 
C-4 and C-5 its relationship to C-5’, and thus the connectivity to N-7 or N-9.   
 22 
  
Figure 10 – Magnified 1H-13C HSQC of N-9 coupled ketone 60   
The HSQC spectrum of ketone 60 (Figure 10) shows a correlation of two methylene 
groups H-2’ and H-4’ with the signal at	𝛿 51.2 ppm, corresponding to two carbon atoms, C-2’ 
and C-4’ in the 13C NMR spectrum.  This is supported by the inherent C2v symmetry that results 
in the two carbon atoms being in an equivalent magnetic environment, whereas the cis- and 
trans-protons are in different chemical environments, giving two distinct signals in the 1H NMR 
spectrum.   
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Figure 11 – Magnified 1H-13C HSQC of aromatic peaks of N-9 coupled ketone 60 
 The aromatic protons, H-8 and H-2, can be distinguished from one another based on 
the correlation of H-5’ with C-8 in the 1H-13C HMBC spectrum, which also shows coupling to 
H-8 in the HSQC spectrum. The C-4 peak can be characterized since it correlates to both H-8 
and H-2 in the HMBC spectrum. 
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Figure 12 –1H-13C HMBC of N-9 coupled ketone 60  
 The HMBC spectrum can be used to characterize the carbons on the 6-chloropurine 
ring, which in turn gives information about connectivity to the cyclobutanone ring, and thus the 
regiochemistry of alkylation at either N-7 or N-9.  The signals associated with C-5 and C-6 can 
be characterized by their correlations in the HMBC spectrum to H-8 and H-2, respectively. 
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Figure 13 –Magnified 1H-13C HMBC of N-9 coupled ketone 60
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Figure 14 –Magnified 1H-13C HMBC of aromatic region of N-9 coupled ketone 60 
As expected, N-9 alkylated ketone 60 shows a correlation of H-5’ with C-4 (Figure 
14).  
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Figure 15 –1H-15N HMBC of N-9 coupled ketone 60 
Furthermore, a 15N NMR study50 of  N-7 and N-9 substituted purine derivatives 
showed the shielding of the alkylated nitrogen by more than	𝛿 80 ppm.  1H-15N HMBC showed a 
correlation between H-5’ and N-9 where N-9 was shielded by a factor of approximately	𝛿 80 ppm 
relative to N-7. The HRMS spectra showed peaks at m/z of 239.0510 and 237.0539, with 
intensities typical of the isotopic abundance of 37Cl and 35Cl (1:3) and an error of less than 1 
ppm.  A fragment at 155.0122 corresponding to the protonated of 6-chloropurine was also 
observed in the MSMS for the parent ion peak of m/z 237.0539.  Furthermore, the X-ray 
structure of the alcohol 62 obtained from reduction of ketone 60 was consistent with alkylation at 
N-9 (vide infra). 
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Figure 16 – 1H NMR spectrum of N-7 coupled ketone 61 
The 1H NMR spectrum of 61 (Figure 16) indicates the presence of protons resembling 
those for 60 in terms of splitting and chemical shifts.  The proton at H-2 is generally more 
deshielded than H-8 as seen for both ketones 60 and 61.  Thus, the 1H NMR spectrum is a clear 
indicator of the regioisomer 60. 
 
Figure 17 – 13C NMR spectrum of N-7 coupled ketone 61 
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The 13C-NMR spectrum of 61 further indicated the presence of at least ten distinct carbon 
centers, with the aromatic carbon signals appearing at d 162.0, 152.6, 148.3, 122.2 ppm and a 
carbonyl carbon at d 202.7 ppm.  One of the aromatic carbons, C-5, shows a greater shielding 
(d 122.8 ppm) relative to C-5 of the N-9 ketone 60 (d 131.6 ppm). The results were consistent 
with trends found in the literature.51–53 
      
Figure 18 –1H-1H COSY of N-7 coupled ketone 61 
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Figure 19 –Magnified1H-1H COSY of cyclobutanone peaks of the N-7 coupled ketone 61 
The COSY spectrum very clearly exhibits the spin-system of H-5’, H-3’, H-2’ and H-
4’ as is associated with cyclobutanones indicating that it did not decompose under basic 
conditions of the N-alkylation step or under prolonged elution times under flash column 
chromatography.  
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Figure 20 –Magnified1H-13C HSQC of cyclobutanone peaks of the N-7 coupled ketone 61 
HSQC shows two correlations of H-2’ and H-4’ to one carbon peak, C-2’ and C4’ which is 
supported by the C2 symmetry of the cyclobutanone, rendering the two carbon atoms equivalent. 
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 Table 1: Comparison of1H NMR and 13C-NMR shifts of 60 and 61 in ppm 
 
The structural assignments of the N-7 and N-9 regioisomers was also supported by 
trends reported in the literature,51–53 in terms of shielding and deshielding of specific nuclei.  The 
C-5 signal is expected to be shielded for the N-7 isomer 61 relative to the N-9 isomer 60 due to 
steric congestion between the C-6 substituted chlorine and N-7, the site of alkylation.  
Furthermore, C-5’, C-4, C-8 and H-8 are expected to be upfield for the N-9 isomer relative to the 
N-7 isomer.  The chemical shifts summarized in table 1 demonstrates that the data are consistent 
with those reported in the literature. 
 
Figure 21- Crystal structure of N-7 ketone 61 
Atom-position N-9 ketone 6 N-7 ketone 61 
C-5’ 3.27 3.32 
C-4 151.8 162.0 
C-5 131.6 122.2 
C-8 144.5 148.3 
H-8 8.17 8.32 
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The crystal structure further confirmed the connectivity of the cyclobutanone ring 
with N-7.  The HRMS spectra further supported the molecular composition of 61 with the 3:1 
isotopic pattern for 35Cl and 37Cl (m/z of 237.0538 and 239.0510 for M+) and fragmentation 
yielding the protonated 6-chloropurine (m/z of 155.0122) in the MSMS spectrum.  The IR 
spectrum exhibits a sharp peak at 1777 cm-1, indicative of a cyclobutanone.  Thus, all of the 
evidence conclusively support the assignment of structure and regiochemistry for the N-7 and N-
9 ketones 60 and 61. 
 
2.5 Reduction of Cyclobutanones 60 and 61 
  Initial attempts to reduce ketones 60 and 61, with sodium borohydride and lithium 
aluminum hydride, yielded two products as evident from TLC with very similar Rf values and 
could not be separated.  It was assumed that both cis and trans alcohols were being formed for 
both regioisomers, 60 and 61.  Thus, we assumed that we could obtain facial selectivity by 
altering, the reagents, solvent and temperature.   
 
Table 2: Reaction conditions and results for reduction of ketones 60 and 61 
Regents Solvents Temperature N-7 ketone (61) N-9 ketone (60) 
NaBH4 MeOH r.t Quantitative 
conversion to cis and 
trans alcohols 
Quantitative 
conversion to cis and 
trans alcohols 
LiAlH4 CH2Cl2 0 oC Sluggish reaction (24 
h +), very low 
product conversion 
Slow reaction (24 h 
+) cis and trans 
alcohol 
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LiAlH4 CH2Cl2 r.t Sluggish reaction (24 
h +), very low 
product conversion 
Sluggish reaction 
(24 h +), very low 
product conversion 
LiAlH4 Et2O 0 oC Fast reaction, 
quantitative 
conversion to cis and 
trans alcohols 
Fast reaction, 
quantitative 
conversion to cis and 
trans alcohols 
NaBH4  0 oC Quantitative 
conversion to cis and 
trans alcohols 
Quantitative 
conversion to cis and 
trans alcohol  
NaBH3CN MeOH r.t Sluggish reaction; 
trace cis and trans 
alcohol 
Sluggish reaction; 
trace cis and trans 
alcohol 
LiAl(OtBu)3H Et2O -78 for 2 h then r.t 
overnight 
 Quantitative 
conversion to cis 
alcohol  
Quantitative 
conversion to cis 
alcohol 
  
Reduction by sodium borohydride and lithium aluminum hydride produced two 
products, in cases where the ketones reacted completely as was noted by the emergence of two 
methylene H-5’ peaks in the 1H NMR spectra of the mixture and two UV-active spots by TLC. 
We proposed that the activation barrier for trans hydride addition would be lower, forming the 
cis alcohol, the kinetic product.  Thus, the use of lower temperatures and bulkier but stronger 
reducing agents would increase stereoselectivity.  Since milder reducing agents such as sodium 
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cyanoborohydride produced a very low product conversion we turned to lithium tri-tert-
butoxyaluminum hydride which has three bulky alkoxy groups and is a single hydride donor.  
Thus we attempted the reduction of ketones 60 and 61 at -78 oC in Et2O which successfully gave 
one stereoisomer quantitatively (Eq.7 & 8).   We reasoned that a greater activation barrier for a 
cis-hydride addition would be required due to steric congestion of the bulky tert-butoxy groups 
and 6-chloropurine in the transition state.  Not surprisingly, trans-addition was observed yielding 
cis alcohols 62 and 63. 
 
 
Figure 22 – 1H NMR spectrum of N-9 alcohol 62 
The NMR spectrum of the cis N-9 alcohol 62 (Figure 22) was consistent with the 
proposed stereoselective reduction based on the methylene shift of d 0.18 ppm from ketone 60 
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(d 4.55 ppm, d) to 62 (d 4.37 ppm, d).  Furthermore, a new proton peak (d 4.27-4.19 ppm, m) 
indicated the hydride attack on the carbonyl carbon, C-1’, that was coupled with the adjacent 
hydrogen atoms on the cyclobutane ring.  
 
Figure 23- Crystal structure of N-9 alcohol 62 
The crystal structure confirmed a cis cyclobutanol 62 (Figure 23) and confirmed a 
trans hydride addition with LiAl(OtBu)3H.  The HRMS spectra also supported the molecular 
composition of 62 and depicts clearly the isotopic signature of 35Cl (m/z of 239.0694 for M+) and 
37Cl (m/z of 241.0655 for M+) also showing fragment ions for 6-chloropurine (m/z of 155.0118  
and m/z of 157.0089) in the MSMS spectra for each parent ion.  Furthermore, the IR spectrum 
showed an absence of the carbonyl peak (1779 cm-1) of 60 and an emergence of a broad 
hydroxyl peak (3358 cm-1).  Thus, all of the evidence was consistent with the assigned regio- and 
stereochemistry for 62. 
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Similarly, reduction of the N-7 regioisomer 61 with LiAl(OtBu)3H was also expected 
to give a cis-alcohol as the kinetic product.  The reduction produced one product that was more 
polar than its ketone counterpart as was evident by TLC.  
         
Figure 24- 1H NMR spectrum of N-7 alcohol 63 
The 1H NMR spectrum (Figure 24) showed the characteristic additional hydrogen 
peak, H-2’, (d 4.30-4.22 ppm, m) and a methylene (H-6’) shift of d 0.18 ppm, from ketone 61 (d 
4.73 ppm) to the alcohol 63 (d 4.55 ppm).   The difference in chemical shift of the methylene 
peaks, H-6’, was exactly the same as that observed between 60 to 62.  This indicated a cis-
configuration, since trans and cis alcohols give different chemical shifts as seen by the 1H NMR 
spectra of the crude material for reduction of 60 and 61 by NaBH4.  The HRMS data is also 
consistent with the molecular composition of 63 and also exhibits a clear isotopic chlorine 
 38 
pattern for 35Cl (m/z of 239.0694 for M+) and 37Cl (m/z of 241.0665 for M+).  The carbonyl peak 
of the N-7 ketone 61 (1777 cm-1) was also absent and a new hydroxyl peak (3443 cm-1) emerged 
in the IR spectrum.  The 13C-NMR spectrum showed the disappearance of the characteristic 
cyclobutanone carbonyl peak (d 207.8ppm). 
 
Figure 25- Crystal structure of N-7 alcohol 64 
The crystal structure of 63 could not be obtained since crystals of adequate size and 
uniformity could not be grown even after considerable effort.  However, in an attempt to grow 
crystals of the cis alcohol alkylated at the N-7 position, another experiment involving the 
reduction of ketone initially with LiAl(OtBu)3H, followed by addition of excess NaBH4 yielded 
the over-reduced alcohol 64 as confirmed by X-ray crystallography (Figure 25).  Similar over-
reductions of purine derivatives have been reported, where electron deficient purines are 
converted to dihydropurine with NaBH4.54  We speculate that the reason for over-reduction of 
the N-7 ketone 61 but not 60 may be associated with steric interaction of 6-chloropurine and the 
cyclobutanone ring, increasing the strain in the N-7 coupled ketone.  This compound was easier 
to crystalize than its precursor 63 and confirmed the reduction of 61 to occur in a trans manner, 
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similar to its N-9 regioisomer 60, giving the cis alcohol 63.  In conclusion, all of the evidence 
acquired supported the molecular composition and stereochemistry of 63. 
 
2.6 Alkylation of purines	
Purine as well as pyrimidine bases can generally alkylate at multiple sites.  
Introduction of heterocycles via a simple SN2 mechanism limits the regioselectivity of the N-
alkylation step by the electronic charge density and steric hindrance in proximity to nitrogen.  
For instance, the parent purinyl anion has a very similar charge distribution for the N-7 and N-9 
position (-0.45:-0.56) and is not sterically hindered due to the lack of substitution on the 
heterocycle.  Thus, it has been shown to give roughly a 1:1 mixture of N-7 and N-9 alkylated 
products.55  Substitution of purine can alter the charge distribution as well as steric hindrance 
around N-7 and N-9, thereby allowing greater regioselectivity in alkylation.   
In the case of purines, substitution at C-6 and N-3 promotes alkylation at N-9 and N-7 
respectively.  Substitution at C-6 with chlorine, peri to N-7, alters the charge distribution of the 
corresponding anion and localizes the charge density on N-9 (ratio of charge localization for N-7 
to N-9 is -0.37:-0.59, respectively) and sterically hinders the N-7 position as can be predicted by 
it’s A-value of 0.52 (free-energy difference between its axial and equatorial conformers of 
substituted cyclohexane).  It also increases the acidity at the N-9 center through inductive effects 
by the meta sigma value (s) of 0.37 for chlorine.  As expected, 6-chloropurine gives the N-9 
alkylated regioisomer as the major product,21 as was also the case for alkylation of 57.  
Several methods have been developed to promote greater regioselectivity for N-alkylation using 
sterically hindered substituents at C-3 and C-6.  Bulky protecting groups such as 2, 3-
dicyclohexylsuccinimidyl (Cy2SI) at C-6 affords N-9 alkylated acylic and cyclic products 
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regioselectively with various substituted purine derivatives.56  Similarly, the formation of N-7 
products is favoured in the case of 6-chloro-3-deaza-3-methyl, a C-3 substituted purine.57 
Others have established the use of microwave excitation to give regioselective 
alkylation with purines as well as pyrimidines.  Khalaf-Nezhad et al. have developed an efficient 
and rapid synthesis of carboacyclic nucleoside analogues using microwave assisted Michael 
addition of a,b-unsaturated esters with adenine and pyrimidine derivatives under solvent-free 
conditions.58  They report the use of tetrabutylammonium bromide (TBAB) as a facilitating agent 
that absorbs microwave irradiation homogenizing the reaction media (Scheme 10). 
 
Similarly, Xia et al. have confirmed the use of microwave excitation to prepare 
carboacyclic nucleoside analogues from alkyl halides and purine and pyrimidine nucleobases in 
water, under short reaction times (Scheme 11).59 
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Our initial attempts towards N-alkylation of nucleobases were to carry these our under 
neutral conditions. The Mitsunobu reaction of several nucleobases with various solvents, 
produced products which exhibit NMR spectra showing multiple alkylation sites.  However, 
these products were either too close in Rf values to separate or no N-alkylation was the outcome 
(Table 3).  
Table 3: Summary of Mitsunobu reaction of 50 with various nucleobases and solvents at room 
temperature. 
Solvent Time duration (h) Base Results 
CH2Cl2 8 5-iodouracil < 1 %  N-alkylation 
CH2Cl2 18 Uracil No N-alkylation 
CH2Cl2 18 6-chloropurine No N-alkylation 
CH2Cl2 18 Adenine No N-alkylation 
DMF Overnight 5-iodouracil Unable to isolate or identify N-alkylation 
DMF Overnight Uracil Unable to isolate or identify N-alkylation 
DMF Overnight Adenine Unable to isolate or identify N-alkylation 
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DMF Overnight Cytosine Unable to isolate or identify N-alkylation 
DMF Overnight Guanine Unable to isolate or identify N-alkylation 
THF Overnight  6-chloropurine No N-alkylation 
 
 
The general procedure (Scheme 12) for the Mitsunobu reaction involves the use of an 
azodicarboxylate, such as diethyl azodicarboxylate (DEAD) or diisopropyl azodicarboxylate 
(DIAD), and triphenylphosphine to displace the OH group of the alcohol by SN2 reaction.  One 
of the last steps in the mechanism involves the deprotonation of the nucleophile to create an 
anion, which then attacks the phosphinium oxide to produce the SN2 product and 
triphenylphosphine oxide. 
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  In general, the factors that affect the distribution of O-vs. N-alkylated products 
include the importance of the individual resonance structures.  Other factors include tautomer 
distribution, solvent and the nature of the electrophile.20,60–63  The relative stabilities of the 
resonance structures that contain the negative charge on oxygen vs. nitrogen are speculated to be 
the cause of the O-vs. N-alkylation distribution.20 
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Chapter 3 
3.0 Photolysis of 60 and 61 
As previously stated, cyclobutanones can undergo a number of photochemical 
transformations.  Three main photochemical pathways include ring-expansion, cycloelimination 
and decarbonylation forming a furanose ring, an alkene, and a cyclopropane respectively 
(Scheme 6).   The objective for photolysis of 60 and 61 was to form ring expansion products as 
isonucleoside analogs. 
 
   The photolysis of both N-7 and N-9 ketones, 60 and 61, under various conditions 
did not yield any ring expansion products (Scheme 13).  
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Previous studies26 have shown that polar solvents, such as acetonitrile and methanol, 
promote ring expansion, whereas non-polar solvents promote cycloelimination.  Decarbonylation 
is promoted by the presence of triplet photosensitizers such as acetone and electron-donating 
groups on the a-position.26,30  Thus, attempts at photolysis of N-9 and N-7 coupled ketones 60 
and 61, respectively, to promote ring expansion products (Scheme 8) were conducted with 
methanol.   Initial experiments included the use of pyrex glass tubes.  However, N-9 coupled 
ketone 60 showed very little product conversion even after 5 h of irradiation.  Thus, further 
experiments were conducted in quartz tubes since quartz is transparent down to 200 nm of light.  
The carbonyl chromophore is excited at 300 nm.  Both ketones displayed similar trends in their 
reactivity.   Exposure to only 15 minutes gave a small amount of product conversion as observed 
by the disappearance of the cyclobutanone peaks (𝛿 3.0-3.28 ppm for 60 and 𝛿 2.94-3.25 ppm for 
61) and the appearance of more shielded peaks (𝛿	1.95-2.75 ppm for photolysis of 60 and 𝛿	1.91-
2.40 ppm for photolysis of 61) in their NMR spectra.  TLC indicated only one major non-polar 
UV active spot for photolysis of both regioisomers.  Prolonged irradiation for 1 h gave NMR 
spectra of the crude that showed a product conversion of more than 60% as seen by the relative 
integration ratios of the methylene protons.  Attempts at isolation of the product were 
unsuccessful even after purification by column chromatography, followed by preparative TLC.  
The products formed were neither cycloelimination products (Scheme 14), as seen by the 
absence of alkene protons, nor ring-expansion products as noted by the absence of a singlet for 
the three methoxy protons. 
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 We speculate the possibility of the products being cyclopropanes, 69 and 70 (scheme 
15), since methylene NMR peaks were more deshielded.  Since the formation of cyclopropanes 
usually occurs by decarbonylation of cyclobutanones in their excited triplet state, we speculate 
that perhaps 6-chloropurine may be acting as a triplet sensitizer.  Prolonged irradiation led to 
decomposition of the ketones as seen by broad NMR signals appearing throughout the aliphatic 
region that did not have integration ratios related to any of the peaks around 𝛿 4-5 ppm of the 
bridging methylene protons, or to the aromatic peaks.   The N-7 ketone 61 showed more rapid 
product conversion than 60, perhaps due to its inherent strain leading to greater reactivity and 
decomposition. 
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Scheme 14: Cycloelimination derived alkene products from photolysis of 60 and 61
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In conclusion, photolysis of ketones 60 and 61 did not produce their expected ring-
expansion counterparts 65 and 66 but rather formed non-polar products that could not be 
completely characterized. 
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Chapter 4 
4.1 Conclusions and Comments  
Cyclobutanones bearing a hydroxymethyl 50 can be readily prepared from a [2+2] 
cycloaddition of a protected allyl alcohol and dichloroketene, generated in situ, followed by 
dechlorination and deprotection.  Compound 50 can be used to synthesize nornucleoside and 
isonucleoside analogs by a variety of methods.  The Mitsunobu reactions were employed in an 
attempt at N-alkylation under neutral conditions.  The products of N-alkylations however, were 
either not formed or were not able to be separated since the Rf values were too close and multiple 
alkylations occurred as observed by the 1H NMR spectra.  Thus, activated alcohols were used in 
an SN2 protocol under basic conditions, with 6-chloropurine as the nucleobase.  Substitution of 
the triflated ketone 57 with a 6-chloropurinyl salt afforded the N-9 and N-7 regioisomers, 60 and 
61 respectively, in reasonable yields.  The relative distribution of the N-9 and N-7 coupled 
ketones were rationalized on the basis charge distribution calculations calculated on N-9 and N-7 
as well as the steric congestion by chlorine, being peri to N-7, for the 6-chloropurinyl anion 59.  
Both regioisomers were confirmed by HRMS, IR and NMR spectroscopy.  A crystal structure of 
61 was also obtained. 
Initial attempts at reduction of ketones 60 and 61 with LiAlH4, NaBH4 and NaBH3CN 
were unsuccessful and produced both cis and trans isomers as seen by TLC and 1H NMR.  These 
could not be separated by column chromatography.  It was speculated that the transition states 
for trans vs. cis hydride addition would have different energies with the use of a bulky hydride 
donor such as LiAl(OtBu)3H.  The reaction successfully provided N-9 and N-7 cis-alcohols 62 
and 63 respectively.  The alcohols were characterized by HRMS, IR and NMR spectroscopy, and 
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a crystal structure of 62 also confirmed a trans hydride addition.  Attempts at crystallizing 63 
sutiable for x-ray diffraction were unsuccessful.  However, in an attempt to grow single crystals 
of N-7 alkylated cis alcohol, the over-reduced cis alcohol 64 with reduced aromaticity was 
formed as confirmed by x-ray crystallography.  This was obtained when excess NaBH4 was 
added after the addition of LiAl(OtBu)3H.  We speculated the reason for over-reduction of N-7 
coupled ketone 61 and not 60 may be associated with steric interaction from the cyclobutanone 
and 6-chloropurine, where chlorine is peri to N-7.  A crystal structure of 64 supported the 
reduction of 61 with LiAl(OtBu)3H to occur in a trans fashion yielding the cis alcohol 63. 
Photolysis of 60 and 61 in MeOH which is known to promote ring-expansion, showed 
products that were less polar and showed more shielded proton signals relative to the ketones in 
their NMR spectra.  The products were speculated to be the decabonylated cyclopropanes 69 and 
70..  The possibility of cycloelimination derived alkene products since no vinyl peaks were 
observed.  Ring-expansion was also ruled out since no methoxy peaks were observed in their 
NMR spectra.  The unusual photodecarbonylation under non-sensitized condtions were 
rationalized in terms of intramolecular triplet photosensitization by the purine chromophore. 
 
4.2 Future Directions 
Derivative 50 can also be used to make other analogs.  Since triflate 57 was extremely 
unstable to moisture, reactions involving polar solvents such as DMSO and DMF for alkylation 
of other polar nucleobases were not practical. It is possible to introduce other nucleobases to 50 
via halogenation by the Appel reaction64 to make 71, followed by displacement of the halogen to 
give 51.  It can then be reduced to make other analogs, or photolysed in the presence of a 
photosensitizer (Scheme 16).   
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 The use of halogenated ketone 71 may serve as a more viable alternative to triflate 57 
and should be more resistant to hydrolysis since the triflate is a better leaving group than the 
halogens.  This should allow the use of other more polar solvents such as DMF and DMSO, in 
which nucleobases are more soluble helping to overcome the solubility issues associated with 
purines and pyrimidines.  The use of microwave irradiation may also assist in homogenizing the 
reaction media and the use of other pyrimidine and purine nucleobases in a regioselective N-
alkylation.58,59  The reasons for enhanced regioselectivity is not known.  Furthermore, the soft 
nature of leaving groups such as iodide and bromide may also complement the nature of the soft 
purinyl anion and further promote N-alkylation according to the HSAB theory.  Subsequently, 
derivative 51 can be reduced stereoselectively by LiAl(OtBu)3H to yield cyclobutane analogs of 
various nucleobases.  The photolysis of 51 where other purine or pyrimidine nucleobases are 
attached, may also be of great interest since it could give further insight to the photochemical 
reactivity of cyclobutanones.  Further experiments to determine the possibility of an 
intramolecular triplet photosensitization can be conducted using an added triplet photosensitizer 
as a control.  Determining the conditions that may promote intramolecular triplet 
Scheme 16: Proposed synthesis of other N-alkylated cyclobutanones and their subsequent reduction and 
photolysis
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photosensitization could also be of great importance in understanding the potential trends in the 
photochemical reactivity of these cyclobutanones. 
 
Ketone 51 can also be used to make five-membered ring analogs by ring-expansion 
by homologation with diazomethane or Baeyer-Villiger oxidation (Scheme 17). 
 
Cyclobutanones are known to undergo ring-expansion by homologation65 quite 
readily with diazomethane, generally generated in situ.66  Due to the inherent symmetry of 51, 
only 74 is expected, with the stereochemistry of 75 being determined in the reduction step.  
Similarly the Baeyer-Villiger oxidation should also form one product 76 with the 
stereochemistry of 77 being governed in reduction to lactol 77 under controlled conditions to 
prevent ring-opening.67   
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Chapter 5 
5.0 Experimental 
5.1 General Experimental 
All chemicals were from Sigma Aldrich Co. and not further purified.  All solvents 
were dried and distilled prior to use.  Reactions were carried out in oven or flame-dried 
glassware under argon unless stated otherwise.  The melting points (mp) were measured on a 
Fisher-Johns melting point apparatus and are uncorrected.  FT-IR spectra were recorded on a 
Bruker Alpha Platinum-ATR as a thin layer of liquid or a thin film of solid introduced by 
dissolving the substrate in chloroform or dichloromethane and applying as a thin layer, followed 
by evaporation.  The mass spectrometry analyses was performed at York University Centre for 
Research in Mass Spectrometry on an Orbitrap Elite Hybrid Ion Trap-Orbitrap Mass 
Spectrometer (ThermoFisher, Waltham, MA) using an electrospray ionization source and helium 
as the collision gas with 50/50 water/methanol solution.  UV-vis spectra were determined using 
methanol as solvent on an Ultrospec 4300 pro UV spectrometer.  X-ray diffraction was carried 
out using a Bruker APEX II CCD diffractometer at the University of Western Ontario (UWO) 
using graphite-monochromated Mo Ka (λ = 0.71073 Ao) for ketone 61 and CuKa(λ = 1.54178 
Ao) for the alcohol 62. 
The1D and 2D- NMR spectra were recorded on Bruker AV 300, Bruker 400 or 
Bruker 700 spectrometer.  The 1HNMR spectra are referenced relative to the solvent residual 
proton signals of CDCl3 (𝛿 7.27), CD3OD (𝛿 3.31) and DMSO-d6 (𝛿 2.50).  The chemical shifts 
are reported as delta (𝛿) values downfield from tetramethylsilane (TMS, 𝛿 = 0) in parts per 
million (ppm).  Data from 1D –H NMR are reported in the following order: chemical shifts (𝛿 in 
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ppm), multiplicity (s = singlet, d = doublet, t = triplet, dd = doublet of doublets, q = quartet, m = 
multiplet), coupling constant (J in Hz), and lastly relative integration (number of protons). 
  Photolyses were carried in quartz tubes strapped around a water-cooled quartz 
immersion well containing a 450-W Hanovia medium pressure mercury arc lamp.  This set-up 
was immersed in an ice-water bath.  Samples were purged with argon for 15 minutes, prior to 
irradiation. 
Analytical thin layer chromatography (TLC) was done using commercial Machery-
Nagel 60 F 254 silica gel coated aluminum sheets and visualization of spots was carried out with 
KMnO4 and/or under UV light (254 nm).  Glass plates coated with Silicycle silica gel 60 F 254 
(40-63 µm particle size) were used for preparative TLC, and Silicycle silica gel (60-200 µm 
particle size) used for column chromatography.   
5.2 Specific Experimental Procedure and Data 
Debenzoylation of ketone 49 
 
  1.66 g (12.0 mmol) of K2CO3 was added to a solution of 1.00 g (10.0 mmol) of 4930 in 
20 mL methanol and the mixture was stirred for 1 h at room temperature.  A solution of saturated 
aqueous solution of NaHCO3 (10 mL) was added and the mixture was stirred for an additional 15 
min.  The solvent was evaporated under vacuum, and the sample was purified by flash column 
chromatography using ethyl acetate to provide 50 in 70% yield.  Its complete characterization 
was not carried out, since it was a known compound.43,68 
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Data for 50 
1H NMR (400 MHz, CDCl3) δ 3.75 (d, J = 6.2 Hz, 2H), 3.14-3.06 (m, 2H), 2.88-2.82 (m, 2H), 
2.69-2.56 (m, 1H) 
IR n = 1775 cm-1 
Triflation of alcohol 50 
 
A solution of 0.100 g (1.00 mmol) 50 in 10 mL of dry CH2Cl2 was cooled to -78 oC 
before adding 0.56 mL (3.20 mmol) of Hunig’s base, followed by 0.17 mL (1.01 mmol)  of 
trifluoromethanesulfonic anhydride.  The mixture was stirred for 10 mins, warmed to 0 oC and 
stirred for 1 h providing quantitative conversion to 57.  The mixture was not purified and 
immediately used for the next step.   
N-Alkylation of 6-chloropurine  
 
A mixture consisting of 0.866 g (5.61 mmol) of 6-chloropurine 5, 0.314 g (5.61 
mmol) of potassium hydroxide, 0.091 g (0.28 mmol) of tris[2-(2-methoxyethoxy)ethyl]amine, 
and 2 g of magnesium sulfate was added to 100 mL of anhydrous acetonitrile.  This mixture was 
stirred overnight, then heated to 60 oC for 5 h and then cooled to room temperature.  Triflate 57 
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1.303 g (5.61 mmol) was added directly as a crude solution from the previous step, and the 
reaction mixture was stirred overnight.  The insoluble material was filtered off, and the solvent 
removed under vacuum.  The residue was purified using 5% methanol and 5% triethylamine in 
chloroform.  The two UV active spots in the TLC were collected and further purified by flash 
column chromatography using ethyl acetate to provide 0.671 g (51%) of N-9 alkylated derivative 
60 and 0.495 g (37%) of N-7 alkylated derivative 61. 
Data for 60 
1H NMR  (700 MHz, CDCl3) δ 8.78 (s, 1H), 8.17 (s, 1H), 4.54 (d, J = 7.6 Hz, 2H), 3.28-3.22 (m, 
2H), 3.15-3.09 (m, 1H), 3.04-3.00 (m, 2H) 
13C NMR (700 MHz, CDCl3) δ 203.5, 152.2, 151.8, 151.5, 144.5, 131.6, 51.2, 48.9, 24.5 
IR n = 3446, 3075, 2926, 1779 cm-1 
HRMS Calculated for C10H10ON4Cl (M+) m/z 237.0539, 239.0510, found 237.0539, 239.0513 
Melting point : 67.1-69.3 oC  
Data for 61 
1H NMR  (400 MHz, CDCl3) 
δ 8.92 (s, 1H), 8.32 (s, 1H), 4.73 (d, J = 7.6, 2H), 3.32-3.25 (m, 2H), 3.21-3.08 (m,        
1H), 3.01-2.94 (m, 2H) 
13C NMR (400 MHz, CDCl3) δ 202.7, 162.0, 152.6, 148.3, 142.8, 122.2, 51.4, 50.7, 25.2 
IR n = 3443, 3104, 3069, 2854, 1777 cm-1 
HRMS Calculated for C10H10ON4Cl (M+) m/z 237.0538, 239.0510, found 237.0538, 239.0512 
Melting point: 115.4-117.7 oC 
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Reduction of N-9 Ketone 60 
 
A of solution of 50 mg (0.21 mmol) of 60 in 10mL of Et2O was cooled to -78 oC and 
81mg (0.32 mmol) of lithium tri-tert-butoxyaluminum hydride was added.  The mixture was 
allowed to warm to room temperature after 2.5 h and was left to stir overnight, to provide 
quantitative conversion to the cis-cyclobutanol 62. 
Data for 62 
1H NMR  (400 MHz, CDCl3) δ 8.76 ( s, 1H), 8.10 (s, 1H), 4.36 (d, J = 7.0, 2H) , 4.27-4.19 (m, 
1H), 2.53-2.47 (m, 2H), 2.44-2.34 (m, 1H), 1.81 (d, J = 5.6, 1H), 1.81-1.74 (m, 2H) 
IR n = 3358, 3113, 3075, 2973, 2929, 2853 cm-1 
HRMS Calculated for C10H20ON4Cl (M+) m/z 239.0694, 241.0665, found 239.0689, 241.00661 
UV  lmax = 206 nm, e = 10676 M-1cm-1 
 
Melting point: 173.5-175 oC 
 
Reduction of N-7 Ketone 61 
A of solution of 50 mg (0.21 mmol) of 61 in 10 mL of Et2O was cooled to -78 oC and 
81 mg (0.32 mmol) of lithium tri-tert-butoxyaluminum hydride was added.  The mixture was 
allowed to warm to room temperature after 2.5 h and was left to stir overnight, to provide 
quantitative conversion to the cis-cyclobutanol 63. 
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Data for 63 
1H NMR (400 MHz, CDCl3) δ 8.89 ( s, 1H), 8.21 (s, 1H), 4.55 (d, J = 7.0, 2H) , 4.30-4.22 (m, 
1H), 2.54-2.48 (m, 2H), 2.45-2.33 (m, 1H), 2.05 (d, J = 5, 1H), 1.79-1.72 (m, 2H) 
13C NMR (400 MHz, CDCl3) δ 161.8, 152.4, 148.6, 142.9, 122.2, 62.9, 52.3, 36.9, 26.7  
IR n = 3364, 3102, 3068, 2974, 2934, 2857 cm-1 
UV lmax = 208 nm, e = 19487 M-1cm-1 
 
Melting point: 175.6-177.6 oC 
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5.4 Appendix 
 
X-ray Structure data for N-7 ketone 61 
Table 1 Crystal data and structure refinement for 61. 
Identification code elrx02 
Empirical formula C10H9ClN4O 
Formula weight 236.66 
Temperature/K 273.15 
Crystal system monoclinic 
Space group P21/c 
a/Å 11.9692(4) 
b/Å 6.8789(3) 
c/Å 12.2719(4) 
α/° 90 
β/° 92.920(3) 
γ/° 90 
Volume/Å3 1009.09(7) 
Z 4 
ρcalcg/cm3 1.558 
μ/mm-1 0.361 
F(000) 488.0 
Crystal size/mm3 ? × ? × ? 
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Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.648 to 82.898 
Index ranges -21 ≤ h ≤ 22, -11 ≤ k ≤ 11, -22 ≤ l ≤ 22 
Reflections collected 55495 
Independent reflections 6450 [Rint = 0.0599, Rsigma = 0.0499] 
Data/restraints/parameters 6450/0/145 
Goodness-of-fit on F2 1.047 
Final R indexes [I>=2σ (I)] R1 = 0.0740, wR2 = 0.1552 
Final R indexes [all data] R1 = 0.1217, wR2 = 0.1792 
Largest diff. peak/hole / e Å-3 1.29/-0.46 
 
 
Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103) for elrx02. Ueq is defined as 1/3 of of the trace of the orthogonalised 
UIJ tensor. 
Atom x y z U(eq) 
Cl0A 2013.0(4) 7138.3(6) 290.5(3) 25.11(10) 
N2 4504.0(11) 12741(2) -596.1(11) 19.5(2) 
C1AA 3391.1(11) 10128(2) -232.9(10) 15.6(2) 
N3 3407.1(10) 11386.5(19) 645.8(10) 16.6(2) 
C3AA 4086.9(12) 11007(2) -991.2(11) 16.7(2) 
N 4306.3(11) 10196(2) -1950.4(10) 20.4(2) 
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N1 3130.6(12) 7528(2) -1470.1(11) 21.4(2) 
C6AA 2917.1(12) 8358(2) -533.1(12) 17.4(2) 
C7AA 4089.1(13) 12899(2) 368.3(12) 18.8(2) 
C 2944.6(12) 11111(2) 1724.7(11) 18.1(2) 
C1 1980.8(12) 12462(2) 1918.1(12) 19.8(3) 
C8AA 3823.3(13) 8486(3) -2122.8(12) 21.5(3) 
C2 852.6(14) 12032(3) 1271.9(14) 27.8(3) 
C3 1421.0(15) 12040(3) 3013.5(14) 28.0(3) 
C4 326.1(15) 11752(3) 2365.6(16) 27.9(3) 
O -614.8(13) 11449(3) 2613.2(17) 48.0(4) 
  
Table 3 Anisotropic Displacement Parameters (Å2×103) for elrx02. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
Cl0A 28.54(19) 24.83(19) 22.37(16) 1.55(14) 5.40(13) -8.20(14) 
N2 21.1(5) 19.0(5) 18.9(5) 1.7(4) 5.3(4) -1.7(4) 
C1AA 16.3(5) 18.5(6) 12.0(5) 0.4(4) 1.8(4) 2.3(4) 
N3 18.6(5) 18.2(5) 13.2(4) 1.0(4) 3.7(4) 0.4(4) 
C3AA 16.6(5) 19.3(6) 14.3(5) 2.2(4) 2.1(4) 1.4(4) 
N 20.3(5) 25.4(6) 15.7(5) -0.1(4) 4.5(4) 1.6(5) 
N1 21.5(5) 23.6(6) 19.1(5) -3.4(4) 1.5(4) -0.4(5) 
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C6AA 18.1(5) 18.3(6) 15.9(5) 1.2(4) 1.0(4) -0.4(5) 
C7AA 20.1(6) 17.1(6) 19.4(6) -1.6(5) 1.8(4) 0.4(5) 
C 20.9(6) 21.5(6) 12.0(5) 1.5(4) 3.1(4) 1.5(5) 
C1 17.9(5) 24.1(7) 17.8(6) 1.8(5) 4.9(4) 1.8(5) 
C8AA 21.6(6) 27.6(7) 15.7(5) -4.3(5) 2.9(5) 1.7(5) 
C2 19.7(6) 40(1) 23.5(7) -0.7(7) 0.5(5) 3.8(6) 
C3 25.5(7) 40.3(10) 19.1(6) 0.5(6) 9.0(5) 3.0(7) 
C4 21.9(7) 27.7(8) 34.9(9) -0.1(7) 9.8(6) -0.1(6) 
O 27.5(7) 56.7(11) 61.5(11) 0.2(9) 19.3(7) -7.8(7) 
  
Table 4 Bond Lengths for elrx02. 
Atom Atom Length/Å   Atom Atom Length/Å 
Cl0A C6AA 1.7343(15)   N C8AA 1.323(2) 
N2 C3AA 1.373(2)   N1 C6AA 1.320(2) 
N2 C7AA 1.3111(19)   N1 C8AA 1.353(2) 
C1AA N3 1.3824(18)   C C1 1.510(2) 
C1AA C3AA 1.4157(19)   C1 C2 1.559(2) 
C1AA C6AA 1.385(2)   C1 C3 1.559(2) 
N3 C7AA 1.376(2)   C2 C4 1.524(3) 
N3 C 1.4732(17)   C3 C4 1.511(3) 
C3AA N 1.3404(19)   C4 O 1.200(2) 
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Table 6 Torsion Angles for elrx02. 
A B C D Angle/˚  A B C D Angle/˚ 
N2 C3AA N C8AA 178.08(14)   C6AA C1AA C3AA N2 -179.86(13) 
C1AA N3 C7AA N2 0.34(18)   C6AA C1AA C3AA N -0.9(2) 
C1AA N3 C C1 -113.39(17)   C6AA N1 C8AA N -1.5(3) 
Table 5 Bond Angles for elrx02. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C7AA N2 C3AA 104.07(12)   N1 C6AA Cl0A 116.89(12) 
N3 C1AA C3AA 105.06(12)   N1 C6AA C1AA 121.13(13) 
N3 C1AA C6AA 138.36(13)   N2 C7AA N3 114.68(13) 
C6AA C1AA C3AA 116.57(12)   N3 C C1 112.77(12) 
C1AA N3 C 129.01(13)   C C1 C2 116.87(14) 
C7AA N3 C1AA 105.40(11)   C C1 C3 112.71(13) 
C7AA N3 C 125.08(13)   C2 C1 C3 90.24(12) 
N2 C3AA C1AA 110.78(12)   N C8AA N1 127.89(14) 
N C3AA N2 126.00(13)   C4 C2 C1 87.84(13) 
N C3AA C1AA 123.21(14)   C4 C3 C1 88.28(13) 
C8AA N C3AA 113.99(13)   C3 C4 C2 93.47(13) 
C6AA N1 C8AA 117.16(14)   O C4 C2 132.9(2) 
C1AA C6AA Cl0A 121.97(11)   O C4 C3 133.62(19) 
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C1AA C3AA N C8AA -0.7(2)   C7AA N2 C3AA C1AA 0.69(16) 
N3 C1AA C3AA N2 -0.50(16)   C7AA N2 C3AA N -178.22(15) 
N3 C1AA C3AA N 178.44(13)   C7AA N3 C C1 76.08(18) 
N3 C1AA C6AA Cl0A 2.9(3)   C N3 C7AA N2 172.73(13) 
N3 C1AA C6AA N1 -177.57(16)   C C1 C2 C4 118.94(15) 
N3 C C1 C2 72.14(17)   C C1 C3 C4 -122.64(15) 
N3 C C1 C3 174.68(14)   C1 C2 C4 C3 -3.26(15) 
C3AA N2 C7AA N3 -0.64(18)   C1 C2 C4 O 175.6(2) 
C3AA C1AA N3 C7AA 0.11(15)   C1 C3 C4 C2 3.26(15) 
C3AA C1AA N3 C -171.86(13)   C1 C3 C4 O -175.6(3) 
C3AA C1AA C6AA Cl0A -178.04(11)   C8AA N1 C6AA Cl0A 179.13(12) 
C3AA C1AA C6AA N1 1.5(2)   C8AA N1 C6AA C1AA -0.4(2) 
C3AA N C8AA N1 2.0(2)   C2 C1 C3 C4 -3.18(15) 
C6AA C1AA N3 C7AA 179.24(17)   C3 C1 C2 C4 3.15(14) 
C6AA C1AA N3 C 7.3(3)             
  
 
Table 7 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for elrx02. 
Atom x y Z U(eq) 
H7AA 4243.49 13950.1 828.32 23 
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HA 3531.94 11326.29 2285.71 22 
HB 2692.04 9777.18 1787.55 22 
H1 2198.68 13829.86 1858.25 24 
H8AA 3979.03 7866.27 -2771.37 26 
H2A 554.69 13128.63 853.69 33 
H2B 862.79 10865.14 828.67 33 
H3A 1698.52 10878.06 3384.14 34 
H3B 1423.04 13141.31 3507.4 34 
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Crystal structure determination of N-7 ketone 61 
 
Crystal Data for C10H9ClN4O (M =236.66 g/mol): monoclinic, space group P21/c (no. 
14), a = 11.9692(4) Å, b =6.8789(3) Å, c =12.2719(4) Å, β = 92.920(3)°, V = 1009.09(7) Å3, Z = 
4, T = 273.15 K, µ(MoKα) = 0.361 mm-1, Dcalc = 1.558 g/cm3, 55495 reflections measured (6.648° 
≤ 2Θ ≤ 82.898°), 6450 unique (Rint = 0.0599, Rsigma = 0.0499) which were used in all calculations. 
The final R1 was 0.0740 (I > 2σ(I)) and wR2 was 0.1792 (all data).  
 
X-ray Structure data for N-9 alcohol 62 
 
Table 1 Crystal data and structure refinement for elrx04. 
Identification code elrx04 
Empirical formula C10H12ClN4O 
Formula weight 239.69 
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Temperature/K 273.15 
Crystal system Monoclinic 
Space group P21/n 
a/Å 12.7276(8) 
b/Å 5.9725(4) 
c/Å 14.8190(10) 
α/° 90 
β/° 108.250(3) 
γ/° 90 
Volume/Å3 1069.81(12) 
Z 4 
ρcalcg/cm3 1.488 
µ/mm-1 3.045 
F(000) 500.0 
Crystal size/mm3 0.504 × 0.211 × 0.073 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 8.012 to 129.852 
Index ranges -14 ≤ h ≤ 14, -4 ≤ k ≤ 7, -17 ≤ l ≤ 17 
Reflections collected 7082 
Independent reflections 1736 [Rint = 0.0448, Rsigma = 0.0269] 
Data/restraints/parameters 1736/0/147 
Goodness-of-fit on F2 1.128 
 72 
Final R indexes [I>=2σ (I)] R1 = 0.0390, wR2 = 0.0991 
Final R indexes [all data] R1 = 0.0468, wR2 = 0.1226 
Largest diff. peak/hole / e Å-3 0.37/-0.35 
 
Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103) for elrx04. Ueq is defined as 1/3 of of the trace of the orthogonalised 
UIJ tensor. 
Atom x y z U(eq) 
Cl1 6597.9(5) 2275.9(12) 2171.9(4) 26.6(3) 
O1 -657.0(13) 5696(3) -1925.0(12) 24.1(5) 
N1 6172.5(16) 5892(4) 1134.5(14) 20.3(5) 
N2 4473.0(17) 7996(4) 653.1(14) 22.2(5) 
N5 3984.2(16) 3286(4) 1958.0(14) 20.5(5) 
N4 3040.8(15) 6277(4) 1187.4(13) 19.5(5) 
C 4082.3(19) 6424(5) 1100.4(16) 19.7(6) 
C1 4656.7(19) 4573(4) 1581.0(15) 17.5(5) 
C2 1259.4(19) 5194(5) -717.6(16) 20.7(6) 
C3 5741.9(19) 4398(5) 1577.9(16) 19.2(6) 
C4 3034.0(19) 4388(4) 1697.9(16) 19.3(6) 
C5 5520(2) 7605(5) 700.6(17) 22.4(6) 
C6 444.3(18) 6481(5) -1549.4(16) 18.6(6) 
C7 1722(2) 7500(5) -315.8(18) 22.1(6) 
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C8 2113(2) 7798(5) 755.0(17) 21.4(6) 
C9 597(2) 8536(5) -908.7(17) 23.1(6) 
  
Table 3 Anisotropic Displacement Parameters (Å2×103) for elrx04. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
Cl1 17.2(4) 32.8(4) 29.6(4) 10.2(3) 7.0(3) 5.3(3) 
O1 14.8(8) 32.2(12) 23.6(9) -9.3(8) 3.7(7) -1.5(7) 
N1 20(1) 21.4(12) 18.8(10) -2.0(9) 5.3(8) -4.3(9) 
N2 22.4(11) 22.8(12) 18.9(10) 2.4(9) 2.8(8) -4.3(9) 
N5 15.9(10) 26.7(13) 18.3(10) 3.9(9) 4.6(8) -2.1(9) 
N4 14.5(10) 25.2(13) 16.4(10) -2.6(9) 1.4(8) 2.6(9) 
C 16.6(11) 26.3(15) 12.7(11) -2.4(10) -0.4(9) -3.2(11) 
C1 16.3(11) 21.7(15) 12.1(10) -1.1(10) 1.1(9) -2.2(10) 
C2 19.3(12) 24.0(15) 18.1(12) -0.7(11) 4.8(9) 1.8(11) 
C3 16.2(11) 25.0(15) 13.4(11) 0.8(10) 0.4(9) -1.3(10) 
C4 16.3(12) 22.9(15) 18.3(11) 0.7(10) 4.7(9) -1.9(10) 
C5 24.1(13) 22.0(15) 19.7(12) 0.3(10) 5.1(10) -6.1(10) 
C6 13.6(11) 24.5(15) 16.9(11) -0.2(10) 3.3(9) 0.8(10) 
C7 18.8(13) 26.0(15) 19.9(12) 1.0(11) 3.6(10) 1.2(11) 
C8 19.2(12) 22.2(14) 20.2(12) 1.5(10) 2.5(10) 2.4(10) 
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C9 21.1(12) 25.5(15) 18.8(12) -0.3(11) 0.7(10) 3.4(11) 
  
Table 4 Bond Lengths for elrx04. 
Atom Atom Length/Å   Atom Atom Length/Å 
Cl1 C3 1.723(3)   N4 C4 1.360(3) 
O1 C6 1.416(3)   N4 C8 1.468(3) 
N1 C3 1.324(3)   C C1 1.392(4) 
N1 C5 1.347(3)   C1 C3 1.387(3) 
N2 C 1.332(3)   C2 C6 1.545(3) 
N2 C5 1.333(3)   C2 C7 1.542(4) 
N5 C1 1.391(3)   C6 C9 1.526(4) 
N5 C4 1.324(3)   C7 C8 1.518(3) 
N4 C 1.374(3)   C7 C9 1.555(3) 
  
Table 5 Bond Angles for elrx04. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C3 N1 C5 117.4(2)   N1 C3 Cl1 117.10(17) 
C N2 C5 111.9(2)   N1 C3 C1 121.2(2) 
C4 N5 C1 103.2(2)   C1 C3 Cl1 121.66(19) 
C N4 C8 125.9(2)   N5 C4 N4 114.2(2) 
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C4 N4 C 106.2(2)   N2 C5 N1 127.9(2) 
C4 N4 C8 127.7(2)   O1 C6 C2 118.9(2) 
N2 C N4 127.8(2)   O1 C6 C9 115.3(2) 
N2 C C1 126.6(2)   C9 C6 C2 88.91(18) 
N4 C C1 105.6(2)   C2 C7 C9 87.98(19) 
N5 C1 C 110.7(2)   C8 C7 C2 118.0(2) 
C3 C1 N5 134.3(2)   C8 C7 C9 119.1(2) 
C3 C1 C 115.0(2)   N4 C8 C7 109.9(2) 
C7 C2 C6 86.8(2)   C6 C9 C7 86.94(19) 
  
Table 6 Torsion Angles for elrx04. 
A B C D Angle/˚   A B C D Angle/˚ 
O1 C6 C9 C7 144.6(2)   C4 N5 C1 C3 -179.6(3) 
N2 C C1 N5 -179.7(2)   C4 N4 C N2 179.7(2) 
N2 C C1 C3 -0.1(4)   C4 N4 C C1 -0.3(2) 
N5 C1 C3 Cl1 -2.9(4)   C4 N4 C8 C7 -107.2(3) 
N5 C1 C3 N1 178.7(3)   C5 N1 C3 Cl1 -177.43(18) 
N4 C C1 N5 0.3(3)   C5 N1 C3 C1 1.1(3) 
N4 C C1 C3 179.9(2)   C5 N2 C N4 -179.3(2) 
C N2 C5 N1 -0.4(4)   C5 N2 C C1 0.7(4) 
C N4 C4 N5 0.3(3)   C6 C2 C7 C8 144.9(2) 
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C N4 C8 C7 68.5(3)   C6 C2 C7 C9 22.67(18) 
C C1 C3 Cl1 177.62(18)   C7 C2 C6 O1 -141.7(2) 
C C1 C3 N1 -0.8(3)   C7 C2 C6 C9 -23.11(18) 
C1 N5 C4 N4 -0.1(3)   C8 N4 C N2 3.3(4) 
C2 C6 C9 C7 22.90(18)   C8 N4 C C1 -176.7(2) 
C2 C7 C8 N4 62.3(3)   C8 N4 C4 N5 176.6(2) 
C2 C7 C9 C6 -22.96(18)   C8 C7 C9 C6 -144.2(2) 
C3 N1 C5 N2 -0.4(4)   C9 C7 C8 N4 166.8(2) 
C4 N5 C1 C -0.1(3)             
 
Table 7 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for elrx04. 
Atom x y z U(eq) 
H1 -671.39 4605.62 -2265.01 36 
H2A 908.69 4375.63 -324.38 25 
H2B 1781.76 4260.77 -901.74 25 
H4 2415.16 3912.18 1851.25 23 
H5 5839.6 8640.67 397.03 27 
H6 768.81 6736.25 -2059.37 22 
H7 2304.78 7959.96 -579.14 27 
H8A 2346.44 9334.3 911.69 26 
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H8B 1510.2 7481.65 1005.45 26 
H9A 60.01 8655.26 -568.7 28 
H9B 662.94 9933.61 -1219.72 28 
 
Crystal structure determination of N-9 alcohol 62 
 
Crystal Data for C10H12ClN4O (M =239.69 g/mol): monoclinic, space group P21/n (no. 
14), a = 12.7276(8) Å, b = 5.9725(4) Å, c = 14.8190(10) Å, β = 108.250(3)°, V = 
1069.81(12) Å3, Z = 4, T = 273.15 K, µ(CuKα) = 3.045 mm-1, Dcalc = 1.488 g/cm3, 7082 
reflections measured (8.012° ≤ 2Θ ≤ 129.852°), 1736 unique (Rint = 0.0448, Rsigma = 0.0269) which 
were used in all calculations. The final R1 was 0.0390 (I > 2σ(I)) and wR2 was 0.1226 (all data). 
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X-ray Structure data for N-7 alcohol 64 
 
Table 1 Crystal data and structure refinement for 64 
Identification code n17088 
Empirical formula C10H13N4OCl 
Formula weight 240.69 
Temperature/K 293(2) 
Crystal system triclinic 
Space group P-1 
a/Å 6.1023(5) 
b/Å 8.5936(6) 
c/Å 10.9942(8) 
α/° 68.952(7) 
β/° 83.796(6) 
γ/° 87.198(6) 
Volume/Å3 534.89(7) 
Z 2 
ρcalcg/cm3 1.494 
µ/mm-1 3.045 
F(000) 252.0 
Crystal size/mm3 ? × ? × ? 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.658 to 130.148 
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Index ranges -7 ≤ h ≤ 5, -10 ≤ k ≤ 10, -12 ≤ l ≤ 12 
Reflections collected 9083 
Independent reflections 1785 [Rint = 0.0297, Rsigma = 0.0161] 
Data/restraints/parameters 1785/0/146 
Goodness-of-fit on F2 1.084 
Final R indexes [I>=2σ (I)] R1 = 0.0515, wR2 = 0.1349 
Final R indexes [all data] R1 = 0.0566, wR2 = 0.1437 
Largest diff. peak/hole / e Å-3 1.08/-0.45 
 
 
Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103) for n17088. Ueq is defined as 1/3 of of the trace of the orthogonalised 
UIJ tensor. 
Atom x y z U(eq) 
Cl0A 1683.7(11) 9180.6(9) 4062.4(7) 25.7(3) 
O1AA 1574(4) 7578(3) 11236(2) 27.8(5) 
N0AA 4842(4) 7161(3) 6459(2) 18.9(5) 
N1 7920(4) 6240(3) 3861(2) 20.1(5) 
C0AA 5141(4) 7253(3) 5168(3) 17.2(6) 
C3AA 7123(5) 6387(3) 4989(3) 18.0(6) 
N2 4816(4) 7849(3) 2899(2) 20.7(5) 
C5AA 6671(5) 7013(4) 2865(3) 21.2(6) 
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C6AA 4060(5) 7988(3) 4073(3) 18.0(6) 
C7AA 6670(5) 6188(4) 7144(3) 21.4(6) 
C2AA 2169(5) 8451(4) 9901(3) 26.6(7) 
N 8030(4) 5773(3) 6130(2) 21.0(5) 
C 627(5) 8206(4) 8984(3) 27.5(7) 
C1 4092(6) 7874(5) 9159(3) 34.9(8) 
C2 2724(6) 7174(5) 7213(3) 34.2(8) 
C3 2643(6) 8270(5) 8002(3) 35.3(8) 
  
Table 3 Anisotropic Displacement Parameters (Å2×103) for n17088. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
Cl0A 21.5(4) 32.4(4) 23.7(4) -11.0(3) -4.8(3) 9.8(3) 
O1AA 27.1(12) 40.8(13) 16.8(10) -11.6(9) -3.9(9) 1.7(9) 
N0AA 16.9(12) 25.9(12) 15.9(12) -10.4(10) -2.1(9) 6.2(9) 
N1 18.9(12) 25.9(13) 16.9(12) -10(1) 1.4(9) 0.3(10) 
C0AA 16.9(14) 19.1(13) 17.1(14) -8.8(11) 0.0(11) -1.5(11) 
C3AA 16.5(14) 19.1(13) 19.1(14) -8.3(11) 0.3(11) -0.5(11) 
N2 21.4(13) 25.7(13) 16.1(12) -8.8(10) -0.8(9) -1.2(10) 
C5AA 22.8(15) 27.3(15) 15.6(14) -11.0(12) 2.0(11) -1.6(12) 
C6AA 16.3(14) 19.9(13) 18.2(14) -7.7(11) -0.6(11) 1.8(11) 
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C7AA 20.5(15) 29.4(15) 17.5(14) -12.3(12) -3.2(11) 5.6(12) 
C2AA 28.0(17) 35.4(17) 17.5(14) -10.8(13) -0.7(12) -2.3(13) 
N 17.3(12) 29.7(13) 17.8(12) -11.3(10) -3.3(9) 9.5(10) 
C 24.8(16) 39.4(18) 21.4(15) -15.1(13) -5.9(13) 11.7(13) 
C1 26.0(17) 53(2) 33.5(18) -25.5(16) -1.7(14) -1.5(15) 
C2 24.9(17) 55(2) 27.0(17) -20.4(16) -2.0(13) 5.9(15) 
C3 33.7(19) 46(2) 28.9(17) -18.2(15) -0.4(14) 3.7(15) 
  
Table 4 Bond Lengths for n17088. 
Atom Atom Length/Å   Atom Atom Length/Å 
Cl0A C6AA 1.732(3)   C3AA N 1.343(4) 
O1AA C2AA 1.404(4)   N2 C5AA 1.315(4) 
N0AA C0AA 1.385(4)   N2 C6AA 1.367(4) 
N0AA C7AA 1.465(4)   C7AA N 1.454(4) 
N0AA C2 1.460(4)   C2AA C 1.524(4) 
N1 C3AA 1.330(4)   C2AA C1 1.521(5) 
N1 C5AA 1.352(4)   C C3 1.536(4) 
C0AA C3AA 1.421(4)   C1 C3 1.556(5) 
C0AA C6AA 1.367(4)   C2 C3 1.489(5) 
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Table 5 Bond Angles for n17088. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C0AA N0AA C7AA 108.4(2)   C0AA C6AA N2 121.7(3) 
C0AA N0AA C2 125.8(2)   N2 C6AA Cl0A 115.5(2) 
C2 N0AA C7AA 118.7(2)   N C7AA N0AA 103.7(2) 
C3AA N1 C5AA 113.7(2)   O1AA C2AA C 114.6(3) 
N0AA C0AA C3AA 108.5(2)   O1AA C2AA C1 121.3(3) 
C6AA C0AA N0AA 136.0(3)   C1 C2AA C 89.3(2) 
C6AA C0AA C3AA 115.5(3)   C3AA N C7AA 110.5(2) 
N1 C3AA C0AA 124.4(3)   C2AA C C3 88.6(2) 
N1 C3AA N 126.7(3)   C2AA C1 C3 87.9(2) 
N C3AA C0AA 108.9(2)   N0AA C2 C3 114.2(3) 
C5AA N2 C6AA 116.7(2)   C C3 C1 87.6(2) 
N2 C5AA N1 127.9(3)   C2 C3 C 119.2(3) 
C0AA C6AA Cl0A 122.8(2)   C2 C3 C1 120.7(3) 
  
Table 6 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for n17088. 
Atom x y z U(eq) 
H1AA 2499.38 7731.42 11668.99 42 
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H5AA 7185.51 6943.75 2058.28 25 
H7AA 7486.05 6843 7496.32 26 
H7AB 6139.08 5188.86 7851.59 26 
H2AA 2302.58 9642.31 9740.36 32 
H 9244.39 5211.53 6245.02 25 
HA -415.02 9116.8 8670.46 33 
HB -112.03 7139.64 9326.99 33 
H1A 4466.17 6702.11 9557.31 42 
H1B 5389.89 8563.69 8956.8 42 
H2A 2385.86 6044.01 7796.55 41 
H2B 1588.25 7537.02 6613.75 41 
H3 2883.52 9426.92 7412.69 42 
 
 
Crystal structure determination of 64 
Crystal Data for C10H13N4OCl (M =240.69 g/mol): triclinic, space group P-1 (no. 2), a = 
6.1023(5) Å, b = 8.5936(6) Å, c = 10.9942(8) Å, α = 68.952(7)°, β = 83.796(6)°, γ = 
87.198(6)°, V = 534.89(7) Å3, Z = 2, T = 293(2) K, µ(CuKα) = 3.045 mm-1, Dcalc = 1.494 g/cm3, 
9083 reflections measured (8.658° ≤ 2Θ ≤ 130.148°), 1785 unique (Rint = 0.0297, Rsigma = 
0.0161) which were used in all calculations. The final R1 was 0.0515 (I > 2σ(I)) and wR2 was 
0.1437 (all data). 
 
 
 
 84 
Crystal structure determination of N-7 alcohol 64 
 
 
 
 
1H NMR, 13C-NMR, MS and IR-spectra 
 
1H NMR spectrum of alcohol 50 (300 MHz, CDCl3) 
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1H NMR spectrum of crude triflate 57 (400 MHz, CDCl3) 
 
 
 
1H NMR spectrum of N-9 coupled ketone 60 (700 MHz, CDCl3) 
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13C-NMR spectrum of N-9 coupled ketone 60 (700 MHz, CDCl3) 
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1H-13C HSQC of N-9 coupled ketone 60 (700 MHz, CDCl3) 
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1H-13C HMBC of N-9 coupled ketone 60 (700 MHz, CDCl3) 
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1H-15N HMBC of N-9 coupled ketone 60 (700 MHz, CDCl3) 
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IR spectrum of N-9 coupled ketone 60 
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HRMS Spectrum of crude N-9 coupled ketone 60 (C10H10ON4Cl+) 
 
 
 
Target (61 with 35Cl) - 237.0539  Observed- 237.0539  Ppm Error < 1 
Target (61 with 37Cl) - 239.0510  Observed- 239.0513  Ppm Error - 1.25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FTMS--N-9   # 1-126 RT: 0.00-1.01 AV: 126 NL: 1.04E6 T: FTMS + p ESI Full ms [50.00-600.00] 
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MSMS of N-9 coupled ketone 60 for peak m/z 237 
 
 
 
 
1H NMR spectrum of N-7 coupled ketone 61 (400 MHz, CDCl3) 
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13C- NMR spectrum of N-7 coupled ketone 61 (400 MHz, CDCl3) 
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1H-1H COSY of N-7 coupled ketone 61 (400 MHz, CDCl3) 
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1H-13C HSQC of N-7 coupled ketone 61 (400 MHz, CDCl3) 
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IR spectrum of N-7 coupled ketone 61 
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HRMS Spectrum of crude N-7 coupled ketone 61 (C10H10ON4Cl+) 
 
 
Target (61 with 35Cl) - 237.0538  Observed- 237.0538  Ppm Error < 1 
Target (61 with 37Cl) - 239.0510  Observed- 239.0512  Ppm Error < 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FTMS--N-7   # 1-249 RT: 0.00-2.00 AV: 249 NL: 1.52E6 T: FTMS + p ESI Full ms [50.00-600.00] 
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MSMS Spectrum of N-7 ketone 61 (C10H10ON4Cl+) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FTMS--N-7--NCE=28   # 1-110 RT: 0.00-1.01 AV: 110 NL: 6.96E5 T: FTMS + p ESI Full ms2 237.00@cid28.00 [65.00-500.00] 
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1H NMR spectrum of N-9 alcohol 62 (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 100 
 
IR spectrum of N-9 alcohol 62  
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UV Spectrum of N-9 alcohol 62 in methanol 
 
 
 
l = 206 nm, e = 10676 M-1cm-1 
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HRMS Spectrum of crude N-9 alcohol 62 (C10H12ON4Cl+) 
 
 
Target (62 with 35Cl) - 239.0694  Observed- 239.0689  Ppm Error- 2.09 
Target (62 with 37Cl) - 241.0665  Observed- 241.0661  Ppm Error- 1.66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Full Scan_N9 
  # 1-58 RT: 0.01-1.01 AV: 58 NL: 1.50E5 T: FTMS + p ESI Full ms [65.00-300.00] 
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MSMS of N-9 alcohol 62 for peak 239m/z 
 
MSMS of N-9 alcohol 62 for peak 241m/z
 
 
 
 
 
 
MSMS_239_N9 #1-108 RT: 0.00-1.00 AV: 108 NL: 2.87E4
T: FTMS + p ESI Full ms2 239.07@cid22.00 [65.00-300.00]
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MSMS_241_N9 #1-108 RT: 0.00-1.00 AV: 108 NL: 8.44E3
T: FTMS + p ESI Full ms2 241.07@cid23.00 [65.00-300.00]
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1H NMR spectrum of N-7 alcohol 63 (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 105 
 
13C- NMR spectrum of N-7 alcohol 63 (400 MHz, CDCl3) 
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IR spectrum of N-7 alcohol 63 
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UV Spectrum of N-7 alcohol 63 in methanol 
 
 
l = 208 nm, e = 19487 M-1cm-1 
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HRMS Spectrum of crude N-7 alcohol 63 (C10H12ON4Cl+) 
 
 
Target (63 with 35Cl) - 239.0694   Observed- 239.0689  Ppm Error- 2.09 
Target (63 with 37Cl) - 241.0665  Observed- 241.0661  Ppm Error- 1.66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Full Scan_N7 
  # 1-90 RT: 0.00-1.00 AV: 90 NL: 3.27E4 T: FTMS + p ESI Full ms [150.00-300.00] 
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MSMS Spectrum of crude N-7 alcohol 63 for 239m/z peak 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MSMS_239_N7 #1-108 RT: 0.01-1.01 AV: 108 NL: 3.24E4
T: FTMS + p ESI Full ms2 239.07@cid24.00 [65.00-300.00]
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MSMS Spectrum of crude N-7 alcohol 63 for 241m/z peak 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MSMS_241_N7 #1-108 RT: 0.00-1.00 AV: 108 NL: 2.20E3
T: FTMS + p ESI Full ms2 241.07@cid22.00 [65.00-300.00]
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1H NMR spectrum of product from photolysis of N-9 ketone 60 in MeOH (CDCl3, 400 MHz) 
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1H NMR spectrum of product from photolysis of N-7 ketone 61 in MeOH (CDCl3, 400 MHz) 
 
 
